Attention deficit/hyperactivity disorder and methylphenidate. A review of height/weight, cardiovascular, and somatic complaint side effects.
about
Effects of FDA advisories on the pharmacologic treatment of ADHD, 2004-2008Long-term exposure to oral methylphenidate or dl-amphetamine mixture in peri-adolescent rhesus monkeys: effects on physiology, behavior, and dopamine system developmentSafety of stimulant treatment in attention deficit hyperactivity disorder: part II.An integrative approach to determine the best behavioral and biological markers of methylphenidate.Methylphenidate has positive hypocholesterolemic and hypotriglyceridemic effects: new data.Dexmethylphenidate for attention deficit hyperactivity disorder.Treating attention-deficit/hyperactivity disorder beyond symptom control alone in children and adolescents: a review of the potential benefits of long-acting stimulantsDopamine transporter genotype and stimulant side effect factors in youth diagnosed with attention-deficit/hyperactivity disorder.Evaluation of risks associated with short- and long-term psychostimulant therapy for treatment of ADHD in children.Methylphenidate HCl: therapy for attention deficit hyperactivity disorder.Drug Holidays From ADHD Medication: International Experience Over the Past Four Decades.Attention-deficit/hyperactivity disorder treatment: what are the long-term cardiovascular risks?ADHD & Pharmacotherapy: Past, Present and Future: A Review of the Changing Landscape of Drug Therapy for Attention Deficit Hyperactivity DisorderDopaminergic and noradrenergic contributions to functionality in ADHD: the role of methylphenidateDrug therapy of attention deficit hyperactivity disorder: current trends.NTP-CERHR Expert Panel Report on the reproductive and developmental toxicity of methylphenidate.Treatment of attention deficit hyperactivity disorder in children and adolescents: safety considerations.Adverse effects of pharmacotherapies for attention-deficit hyperactivity disorder: epidemiology, prevention and management.Early postnatal exposure to methylphenidate alters stress reactivity and increases hippocampal ectopic granule cells in adult rats.Side effects of methylphenidate in childhood cancer survivors: a randomized placebo-controlled trial.Current issues around the pharmacotherapy of ADHD in children and adults.Switching from oral extended-release methylphenidate to the methylphenidate transdermal system: continued attention-deficit/hyperactivity disorder symptom control and tolerability after abrupt conversion.Cardiovascular effects of medications for the treatment of attention-deficit hyperactivity disorder: what is known and how should it influence prescribing in children?Cardiovascular effects of methylphenidate, amphetamines and atomoxetine in the treatment of attention-deficit hyperactivity disorder.Achieving remission as a routine goal of pharmacotherapy in attention-deficit hyperactivity disorder.The use of stimulant medication to treat neurocognitive deficits in patients with pediatric cancer, traumatic brain injury, and sickle cell disease: a review.Managing the risks of ADHD treatments.The Effectiveness of an Interpersonal Cognitive Problem-Solving Strategy on Behavior and Emotional Problems in Children with Attention Deficit Hyperactivity.[Attention deficit disorder and hyperactivity: does the treatment affect the statural growth?].Behavioral response to methylphenidate challenge: influence of early life parental care.Juvenile toxicity assessment of d,l-methylphenidate in rats.Effect of methylphenidate treatment on appetite and levels of leptin, ghrelin, adiponectin, and brain-derived neurotrophic factor in children and adolescents with attention deficit and hyperactivity disorder.Pharmacologic management of attention deficit hyperactivity disorder in children and adolescents: a review for practitioners.Neuropsychological Deficits Are Not Predictive of Deficient Emotional Self-Regulation in Adults With ADHD.Neurotrophin 3 genotype and emotional adverse effects of osmotic-release oral system methylphenidate (OROS-MPH) in children with attention-deficit/hyperactivity disorder.Gait in attention deficit hyperactivity disorder : effects of methylphenidate and dual tasking.Subjective Report of Side Effects of Prescribed and Nonprescribed Psychostimulant Use in Young Adults.
P2860
Q28283341-9E23FD45-8854-43F5-B24F-461258415401Q28389867-BB991DB4-4155-4413-B16D-14097CA692BCQ30451303-561E4177-9A48-44B1-9AB8-AF0CFDC3C356Q33283331-024E442A-CD45-433A-95CC-4479A3583D2CQ33474263-0F4B41CF-251E-4C3A-ADE1-FB83C5FBD1C2Q33513714-1308B978-A401-41AD-9DF3-43FE81A59DFDQ33746664-F121138E-63EE-4606-8AF4-531D4EE30A6DQ33799533-AB31E5BE-4223-4FB1-BE0F-CB402A969B48Q34303865-3C42228D-413C-457E-B270-BE0BC83BEFFBQ34424163-4E7EE3D1-77AC-440A-8BF6-4A22B7135E4FQ34440332-F1EC3865-10EA-46ED-8232-8D6B70256B15Q34461113-F1B8C494-9107-4ED0-94A4-C867789D5DADQ34493964-CDC1F453-3DB7-4921-97AD-A0402C2E25B3Q34991378-17288629-ACA1-4544-9FD6-67484AA8DBD7Q35964370-3C757BAD-A1AA-436A-9595-928E416CD85FQ36243099-42B3547E-5C37-451D-AD57-6CF4CD7FFE02Q36694580-E7523E50-3F26-4FDA-B902-01FF75B5A834Q37085902-0CAEC118-075B-47BE-AC06-2EB64C5BA07CQ37146492-63CBD377-115C-485D-A7E2-ED5287CB5A31Q37248566-44472748-7DC5-494A-B672-85046BDE8DDBQ37314533-412E9F77-6988-4557-9F69-90DC195216A4Q37419717-C9E654BA-9E87-4968-A019-192CA06943F4Q37756113-EECE22AB-8F45-49A5-9A27-E058429447E7Q37784796-545D7C28-AD87-4FAE-8E09-2486EFE89CEAQ37815474-3DEED9DF-24C7-4699-8F44-EA2F97906170Q38055294-6FF895B6-B903-4B0A-9C44-90BF75E4A495Q38241131-7890AD8A-61BB-4B93-83A4-05613AAC12FFQ38866017-0169656C-3E42-4FA1-B183-AD5B5327D846Q43045659-86590147-1628-47B6-A8C0-91139F436B2DQ45984800-3AF9895B-44B0-4350-94E0-A8608F3B0261Q46812561-C8F5A2E7-C469-4089-BE99-FB5ABBBB811EQ48678229-F7E52933-26EA-48F9-BE97-C46A95CA82AAQ50021450-B3B955D1-714B-47B6-BA33-394EB4CDD500Q50532020-6A403C41-0AEC-4E9A-903E-01169AE788F2Q50533661-01BADEFF-0E74-4826-B0F7-FA984C69FB97Q53816633-C6FCD250-CE3A-4046-A5C2-CCA1E5A0DF6DQ55220222-237BD16C-36F3-4962-8CBD-BE521227BD70
P2860
Attention deficit/hyperactivity disorder and methylphenidate. A review of height/weight, cardiovascular, and somatic complaint side effects.
description
2002 nî lūn-bûn
@nan
2002 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Attention deficit/hyperactivit ...... omatic complaint side effects.
@ast
Attention deficit/hyperactivit ...... omatic complaint side effects.
@en
type
label
Attention deficit/hyperactivit ...... omatic complaint side effects.
@ast
Attention deficit/hyperactivit ...... omatic complaint side effects.
@en
prefLabel
Attention deficit/hyperactivit ...... omatic complaint side effects.
@ast
Attention deficit/hyperactivit ...... omatic complaint side effects.
@en
P1476
Attention deficit/hyperactivit ...... omatic complaint side effects.
@en
P2093
Catherine Moffitt
Mark D Rapport
P304
P356
10.1016/S0272-7358(02)00129-0
P577
2002-11-01T00:00:00Z